July 06, 2026 CMS Launches Medicare Pilot Program for GLP-1s CMS began covering certain GLP-1 medications through a new Medicare pilot program that launched this month.
June 23, 2026 HHS Aims to Bolster Clinical Research, Drug Development The U.S. Department of Health and Human Services this week announced a department-wide initiative to accelerate early- and late-stage drug development and expand domestic clinical research.
June 15, 2026 CMS: Medicare Drug Price Negotiation is Here to Stay CMS is looking to make the Medicare Drug Price Negotiation Program permanent through a new proposed rule.
April 13, 2026 CMS Proposes New Standards for Drug Prior Authorization A new CMS proposed rule would require insurers to process prior authorization requests for drugs more quickly and publish approval and denial rates.
March 17, 2026 Round 3 Medicare Drug Price Negotiations Begin The manufacturers of the 15 drugs selected for the next round of Medicare price negotiations all agreed to come to the table, setting the stage for the next phase to begin.
February 09, 2026 What to Know: A Primer on TrumpRx The White House last week unveiled a new direct-to-consumer prescription drug site as part of a larger effort to address rising drug prices.
January 28, 2026 CMS Picks Next Drugs for Medicare Price Negotiations CMS this week announced the next 15 prescription drugs selected to participate in its Medicare drug price negotiation program for 2026.
January 16, 2026 What’s in the White House’s Health Care Affordability Plan? The White House unveiled a health care framework focused on drug prices, insurance premiums, and transparency measures this week.
December 03, 2025 CMS Announces Savings from Medicare Price Negotiation Program CMS will save $12 billion on the 15 commonly used drugs included in the second phase of the agency’s price negotiation program, federal officials announced late last month.
November 25, 2025 5 Fast Facts: GLP-1 Drugs on Health Care Costs Earlier this month, the Trump administration made moves to address the rising cost of the popular GLP-1 drugs by negotiating deals with two of the largest manufacturers, Eli Lilly and Novo Nordisk.